Clinical trials: Liver Diseases, Alcoholic
Non-alcoholic Fatty Liver Disease
The Effects of PXR Activation on Hepatic Fat Content
This study investigates the effects of pregnane X receptor (PXR) activation on hepatic fat content in healthy volunteers. Rifampicin (an antibiotic and also an efficient PXR activator) and placebo will be given for a week to…
- Trial name
- NCT02329405
- Testing
- Rifampicin
- Where
- Finland
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Oulu
Non-Alcoholic Fatty Liver Disease
Motivational Interviewing in the Management of Non Alcoholic Fatty Liver Disease
The goal of this study is to assess if motivational counselling works to reduce the weight in participants with Non Alcoholic Fatty Liver Disease (NAFLD).
- Trial name
- NCT06348628
- Testing
- Motivational Interview
- Where
- Sri Lanka
- Volunteers
- 231 people
- Sponsor
- Madunil Anuk Niriella
Cirrhosis
Correlation of Hepatitis C, Alcoholic Liver Disease, and Renal Failure With Hyperfibrinolysis in Liver Failure
1. Further characterize the incidence of hyperfibrinolysis in cirrhotics 2. Correlate hyperfibrinolysis with 1. hepatitis C 2. alcoholic liver disease 3. the subset of a\&b with renal failure with and without dialysis 3.
- Trial name
- NCT02737345
- Testing
- Rotem
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Scott Allen
Hepatic Encephalopathy, Cirrhosis
Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome
Investigating the impact of hepatic encephalopathy on default mode networks within the brain to provide more clues with understanding the physiology of consciousness and predicting the reversibility of comatose states.
- Conditions
- Hepatic Encephalopathy, Cirrhosis, Nonalcoholic Steatohepatitis, Hepatitis C
- Trial name
- NCT02083367
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- OSF Healthcare System
Non-Alcoholic Fatty Liver Disease
Microbiome-Mediated Gut Dysfunction in Non-Alcoholic Fatty Liver Disease
This study is designed to generate the first human evidence to date on microbiota encroachment in non-alcoholic fatty liver disease.
- Trial name
- MODIFY (NCT05209100)
- Testing
- Sigmoidoscopy
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- AdventHealth Translational Research Institute
Non Alcoholic Steatohepatitis
The Effects of Flaxseed Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
To study the effects of Flaxseed supplement on lipid profile, liver enzymes, inflammatory factors and hepatic fibrosis in patients with Nonalcoholic Steatohepatitis (NASH), 50 patients who referred to Gastrointestinal (GI) clinic…
- Trial name
- NCT02395900
- Testing
- Flaxseed, control
- Volunteers
- 50 people
- Sponsor
- National Nutrition and Food Technology Institute
Alcoholic Liver Cirrhosis
REVIVE(Randomized Exploratory Clinical Trial to Evaluate the Safety and Effectiveness of Stem Cell Product in Alcoholic Liver Cirrhosis Patient)
If the participant voluntarily agrees to participate in the clinical trial before registration, the investigator conducts a screening test to evaluate the participant's suitability.
- Trial name
- NCT01875081
- Testing
- Livercellgram
- Where
- South Korea
- Volunteers
- 72 people
- Sponsor
- Pharmicell Co., Ltd.
Antipsychotic Induced Weight Gain, Non-alcoholic Steatohepatitis (NASH)
Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant
The primary objective of this study is to evaluate the pharmacokinetics (PK) of miricorilant in the presence and absence of the strong cytochrome P450 [(CYP) 2C19] inhibitor, fluvoxamine, in healthy participants.
- Trial name
- NCT05712265
- Testing
- Miricorilant, Fluvoxamine
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Type 2 Diabetes, Non-Alcoholic Fatty Liver Disease
Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease
This study is a randomized, non-blinded clinical trial specifically designed to assess the initial feasibility and efficacy of SGLT2 inhibitors in treating NAFLD among adults diagnosed with type 2 diabetes.
- Trial name
- NCT06218342
- Testing
- Henagliflozin, Background medication
- Volunteers
- 156 people
- Sponsor
- Sir Run Run Shaw Hospital
Hepatic Steatosis
A Pilot, Dose Escalating Study on VLX103 in Moderate Alcoholic Steatohepatitis
The study drug (VLX103) is being developed for the treatment of Alcoholic Steatohepatitis and other liver diseases. Alcoholic Steatohepatitis is an inflammatory (associated with irritation, swelling and cell damage) disease that…
- Trial name
- NCT03201159
- Testing
- VLX103
- Where
- United States
- Sponsor
- Gyongyi Szabo
Type 2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease
Diabetes, Exercise and Liver Fat (DELIVER)
This randomised controlled trial will determine if exercise (150 - 200 min per week, 6 weeks) can beneficially modify liver fat quality in non alcohol fatty liver disease patients with type 2 diabetes mellitus (n = 26, 13 per…
- Conditions
- Type 2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, Obesity, Insulin Resistance
- Trial name
- (DELIVER) (NCT04004273)
- Testing
- Exercise
- Where
- 4 sites in United Kingdom
- Volunteers
- 25 people
- Sponsor
- James King
Obesity, Morbid, NASH - Nonalcoholic Steatohepatitis
Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity
This study is being done to better understand the relationship between inflammation in adipose tissue (AT), abnormal deposition of fat around the liver and how this affects its appearance and function and ultimately insulin…
- Conditions
- Obesity, Morbid, NASH - Nonalcoholic Steatohepatitis, Chronic Inflammation
- Trial name
- NCT04232566
- Testing
- Bariatric surgery
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Non-Alcoholic Fatty Liver Disease, Liver Diseases
Identification and Characterization of NAFLD in Turkey
Non-alcoholic fatty liver disease (NAFLD) is with 25% the most prevalent liver disorder in Western society and is associated with overweight, obesity, metabolic syndrome (MetS), type 2 diabetes mellitus (T2DM) and cardiovascular…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Liver Diseases, Fatty Liver, Metabolic Syndrome
- Trial name
- NCT05194553
- Where
- Turkey (Türkiye)
- Volunteers
- 450 people
- Sponsor
- Maastricht University
Non-Alcoholic Fatty Liver Disease
Plant Sterols and Plant Stanols and Liver Inflammation
As the prevalence of obesity is reaching epidemic proportions, the prevalence of non-alcoholic fatty liver disease (NAFLD), including non-alcoholic steatohepatitis (NASH), increases concomitantly and becomes a major global health…
- Trial name
- NCT03627819
- Testing
- Plant sterol-enriched margarine, Plant stanol-enriched margarine, Control margarine
- Where
- Netherlands
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Menopause, Non Alcholic Fatty Liver Disease
MHT and Liver Function in Postmenopausal Women
This prospective study aims to evaluate the effects of menopausal hormone therapy (MHT) on liver function, lipid profiles, and hepatic steatosis in postmenopausal women.
- Conditions
- Menopause, Non Alcholic Fatty Liver Disease, Hepatic Steatosis
- Trial name
- NCT07103603
- Testing
- Menopausal hormone therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 44 people
- Sponsor
- Ipek B. Ozcivit Erkan, MD
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
The study will assess the efficacy and safety of 2 dose regimens of pegozafermin compared to placebo for the treatment of liver fibrosis stage F2 or F3 in adult participants with MASH.
- Trial name
- NCT06318169
- Testing
- Pegozafermin
- Where
- 370 sites in United States, Argentina and 25 more
- Volunteers
- 1,350 people
- Sponsor
- Hoffmann-La Roche
Non-Alcoholic Steatohepatitis
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis
A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of EDP-305 in subjects with Non-Alcoholic Steatohepatitis
- Trial name
- NCT03421431
- Testing
- EDP-305 Dose 1, EDP-305 Dose 2
- Where
- 82 sites in United States, Canada and 4 more
- Volunteers
- 134 people
- Sponsor
- Enanta Pharmaceuticals, Inc
Steatohepatitis, Nonalcoholic, Osteo Arthritis
DDI Study of ECC0509 With Metformin, Midazolam, and Caffeine
This is a Phase 1, open-label, 2-part, fixed-sequence, single-center, two-period, drug-drug interaction trial in healthy adult participants to determine if ECC0509 administration at steady state affects the pharmacokinetics (PK)…
- Trial name
- NCT07873229
- Testing
- ECC0509, Metformin, Caffeine
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eccogene
Non Alcoholic Fatty Liver Disease
Mastiha Treatment for Obese With NAFLD Diagnosis
NAFLD/NASH is one of the most common complications of obesity and diabetes mellitus in Western populations affecting approximately 50% of diabetics and 76% of obese patients.
- Trial name
- MAST4HEALTH (NCT03135873)
- Testing
- Mastiha
- Where
- Greece
- Volunteers
- 100 people
- Sponsor
- Harokopio University
Non Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis
Glucose-induced Glucagon-like Peptide 1 (GLP-1) Secretion in NAFLD Patients Compared to Healthy Controls
The incretin effect is impaired in patients with type 2 diabetes mellitus (T2DM), thus GLP-1 receptor agonists are used for the treatment of T2DM.
- Trial name
- NCT01674972
- Testing
- Oral glucose tolerance test
- Where
- Switzerland
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.